Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLPG5885
- Development stage
- Discontinued
- Lead developer
- Galapagos
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GLPG5885 is an investigational "armed" bispecific chimeric antigen receptor T-cell (CAR-T) therapy developed by Galapagos for the treatment of B-cell malignancies. The construct is designed as a bispecific CAR, meaning it is engineered to recognize and bind to two distinct antigens on the surface of malignant B-cells, a strategy intended to reduce the risk of relapse due to antigen escape. The "armed" component of the therapy typically refers to additional genetic modifications intended to enhance the CAR-T cells' persistence, expansion, or potency within the immunosuppressive tumor microenvironment. In October 2025, Galapagos announced a strategic decision to wind down its cell therapy activities, leading to the discontinuation of the GLPG5885 program as of early 2026.
- Other names
- armed bi-specific CAR-T-cell therapy
02
Targets
Beyond the preview
Go deeper on GLPG5885.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLPG5885.